David A. Holland
Papers
1
Total Citations
6
H-Index
1
About
David A. Holland is a leading researcher in analytical biotechnology, with a primary focus on the quality control and safety assessment of mRNA-based therapeutics. His most impactful work centers on the development of novel immunoassays for detecting critical impurities in mRNA vaccines. Holland’s landmark 2024 study introduced an automated sandwich ELISA method for quantifying residual double-stranded RNA (dsRNA)—a problematic byproduct of in vitro transcription that can compromise vaccine potency and patient safety. This contribution, already garnering 6 citations in its first year, addresses a pressing regulatory and manufacturing challenge as mRNA technology expands globally. By enabling rapid, high-throughput detection of dsRNA impurities, Holland’s work directly supports the scalable production of safer, more effective mRNA vaccines. His research bridges the gap between analytical chemistry and pharmaceutical development, providing essential tools for both academic labs and industrial manufacturing. Holland’s achievements position him at the forefront of ensuring the quality and reliability of next-generation vaccines, making his work indispensable for researchers and manufacturers navigating the complexities of mRNA-based medicine.
Research Focus
Key Achievements
Top Papers
- 1